159 related articles for article (PubMed ID: 31281064)
1. High Endogenous DNA Damage Levels Predict Hematological Toxicity in Testicular Germ Cell Tumor Patients Treated With First-Line Chemotherapy.
Hapakova N; Sestakova Z; Holickova A; Hurbanova L; Miskovska V; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Obertova J; Palacka P; Sycova-Mila Z; Mardiak J; Chovanec M; Mego M
Clin Genitourin Cancer; 2019 Oct; 17(5):e1020-e1025. PubMed ID: 31281064
[TBL] [Abstract][Full Text] [Related]
2. Are Changes in the Percentage of Specific Leukocyte Subpopulations Associated with Endogenous DNA Damage Levels in Testicular Cancer Patients?
Kalavska K; Sestakova Z; Mlcakova A; Kozics K; Gronesova P; Hurbanova L; Miskovska V; Rejlekova K; Svetlovska D; Sycova-Mila Z; Obertova J; Palacka P; Mardiak J; Chovanec M; Chovanec M; Mego M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34361047
[TBL] [Abstract][Full Text] [Related]
3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours.
Rudolph C; Melau C; Nielsen JE; Vile Jensen K; Liu D; Pena-Diaz J; Rajpert-De Meyts E; Rasmussen LJ; Jørgensen A
Cell Oncol (Dordr); 2017 Aug; 40(4):341-355. PubMed ID: 28536927
[TBL] [Abstract][Full Text] [Related]
5. [Colony stimulating factors in polychemotherapy of testicular tumors. A comparison between G-CSF and GM-CSF].
Will R; Hofmockel G; Langer W; Frohmüller H
Urologe A; 1999 May; 38(3):258-63. PubMed ID: 10407985
[TBL] [Abstract][Full Text] [Related]
6. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model.
Jørgensen A; Blomberg Jensen M; Nielsen JE; Juul A; Rajpert-De Meyts E
J Steroid Biochem Mol Biol; 2013 Jul; 136():238-46. PubMed ID: 23098692
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced toxicity in patients with testicular germ cell tumors: The impact of physical fitness and regular exercise.
Amiri A; Chovanec M; Oliva V; Sedliak M; Mego M; Ukropec J; Ukropcová B
Andrology; 2021 Nov; 9(6):1879-1892. PubMed ID: 34245663
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of DNA damage level in peripheral blood lymphocytes of chemotherapy-naïve patients with germ cell cancer.
Sestakova Z; Kalavska K; Hurbanova L; Jurkovicova D; Gursky J; Chovanec M; Svetlovska D; Miskovska V; Obertova J; Palacka P; Rejlekova K; Sycova-Mila Z; Cingelova S; Spanik S; Mardiak J; Chovanec M; Mego M
Oncotarget; 2016 Nov; 7(46):75996-76005. PubMed ID: 27732956
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma.
Harstrick A; Schmoll HJ; Bokemeyer C; Metzner B; Illiger HJ; Berdel W; Ostermann H; Manegold C; Räth U; Siegert W
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S198-202. PubMed ID: 1665492
[TBL] [Abstract][Full Text] [Related]
10. First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.
Tanaka H; Yuasa T; Fujii Y; Sakura M; Urakami S; Yamamoto S; Masuda H; Fukui I; Yonese J
Chemotherapy; 2013; 59(6):441-6. PubMed ID: 25060582
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
12. Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.
Schmidtova S; Kalavska K; Kucerova L
Curr Oncol Rep; 2018 Sep; 20(11):88. PubMed ID: 30259297
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer.
Nitzsche B; Gloesenkamp C; Schrader M; Hoffmann B; Zengerling F; Balabanov S; Honecker F; Höpfner M
Br J Cancer; 2012 Nov; 107(11):1853-63. PubMed ID: 23169338
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
15. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors.
Cavallo F; Feldman DR; Barchi M
Int J Dev Biol; 2013; 57(2-4):273-80. PubMed ID: 23784838
[TBL] [Abstract][Full Text] [Related]
16. Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?
Suer E; Mermerkaya M; Gülpınar Ö; Afandiyev F; Baltacı S; Türkölmez K; Bedük Y
J Urol; 2013 Dec; 190(6):2081-5. PubMed ID: 23764076
[TBL] [Abstract][Full Text] [Related]
17. Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples.
Lobo J; Constâncio V; Leite-Silva P; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
Clin Epigenetics; 2021 Apr; 13(1):70. PubMed ID: 33823933
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular events in survivors of high-dose chemotherapy for germ cell tumors.
Ishioka J; Fujii Y; Kageyama Y; Fukuda H; Higashi Y; Kihara K
Int J Urol; 2008 Jul; 15(7):642-5. PubMed ID: 18643784
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
[TBL] [Abstract][Full Text] [Related]
20. Changes in cellular immunity during chemotherapy for testicular cancer.
Kubota Y; Ohji H; Itoh K; Sasagawa I; Nakada T
Int J Urol; 2001 Nov; 8(11):604-8. PubMed ID: 11903686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
